Literature DB >> 35213008

Antisense RNA Therapeutics: A Brief Overview.

Virginia Arechavala-Gomeza1,2, Alejandro Garanto3,4,5.   

Abstract

Nucleic acid therapeutics is a growing field aiming to treat human conditions that has gained special attention due to the successful development of mRNA vaccines against SARS-CoV-2. Another type of nucleic acid therapeutics is antisense oligonucleotides, versatile tools that can be used in multiple ways to target pre-mRNA and mRNA. While some years ago these molecules were just considered a useful research tool and a curiosity in the clinical market, this has rapidly changed. These molecules are promising strategies for personalized treatments for rare genetic diseases and they are in development for very common disorders too. In this chapter, we provide a brief description of the different mechanisms of action of these RNA therapeutic molecules, with clear examples at preclinical and clinical stages.
© 2022. The Author(s).

Entities:  

Keywords:  Antisense oligonucleotides; Clinical trials; Personalized medicine; RNA therapy; Splicing

Mesh:

Substances:

Year:  2022        PMID: 35213008     DOI: 10.1007/978-1-0716-2010-6_2

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  59 in total

1.  Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients.

Authors:  Maki Goto; Daisuke Sawamura; Wataru Nishie; Kaori Sakai; James R McMillan; Masashi Akiyama; Hiroshi Shimizu
Journal:  J Invest Dermatol       Date:  2006-06-15       Impact factor: 8.551

2.  QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.

Authors:  Olivier Bornert; Marieke Hogervorst; Pauline Nauroy; Johannes Bischof; Jim Swildens; Ioannis Athanasiou; Sara F Tufa; Douglas R Keene; Dimitra Kiritsi; Stefan Hainzl; Eva M Murauer; M Peter Marinkovich; Gerard Platenburg; Ingrid Hausser; Verena Wally; Tita Ritsema; Ulrich Koller; Elisabeth M Haisma; Alexander Nyström
Journal:  J Invest Dermatol       Date:  2020-09-16       Impact factor: 8.551

Review 3.  Casimersen: First Approval.

Authors:  Matt Shirley
Journal:  Drugs       Date:  2021-04-16       Impact factor: 9.546

4.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Authors:  Sebahattin Cirak; Virginia Arechavala-Gomeza; Michela Guglieri; Lucy Feng; Silvia Torelli; Karen Anthony; Stephen Abbs; Maria Elena Garralda; John Bourke; Dominic J Wells; George Dickson; Matthew J A Wood; Steve D Wilton; Volker Straub; Ryszard Kole; Stephen B Shrewsbury; Caroline Sewry; Jennifer E Morgan; Kate Bushby; Francesco Muntoni
Journal:  Lancet       Date:  2011-07-23       Impact factor: 79.321

5.  Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.

Authors:  V Arechavala-Gomeza; I R Graham; L J Popplewell; A M Adams; A Aartsma-Rus; M Kinali; J E Morgan; J C van Deutekom; S D Wilton; G Dickson; F Muntoni
Journal:  Hum Gene Ther       Date:  2007-09       Impact factor: 5.695

Review 6.  The missing puzzle piece: splicing mutations.

Authors:  Marzena A Lewandowska
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

7.  Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.

Authors:  Linda J Popplewell; Carl Adkin; Virginia Arechavala-Gomeza; Annemieke Aartsma-Rus; Christa L de Winter; Steve D Wilton; Jennifer E Morgan; Francesco Muntoni; Ian R Graham; George Dickson
Journal:  Neuromuscul Disord       Date:  2010-01-15       Impact factor: 4.296

Review 8.  Splicing modulation therapy in the treatment of genetic diseases.

Authors:  Virginia Arechavala-Gomeza; Bernard Khoo; Annemieke Aartsma-Rus
Journal:  Appl Clin Genet       Date:  2014-12-04

9.  Antisense oligonucleotide-based treatment of retinitis pigmentosa caused by USH2A exon 13 mutations.

Authors:  Kalyan Dulla; Ralph Slijkerman; Hester C van Diepen; Silvia Albert; Margo Dona; Wouter Beumer; Janne J Turunen; Hee Lam Chan; Iris A Schulkens; Lars Vorthoren; Cathaline den Besten; Levi Buil; Iris Schmidt; Jiayi Miao; Hanka Venselaar; Jingjing Zang; Stephan C F Neuhauss; Theo Peters; Sanne Broekman; Ronald Pennings; Hannie Kremer; Gerard Platenburg; Peter Adamson; Erik de Vrieze; Erwin van Wijk
Journal:  Mol Ther       Date:  2021-04-23       Impact factor: 12.910

10.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.

Authors:  Maria Kinali; Virginia Arechavala-Gomeza; Lucy Feng; Sebahattin Cirak; David Hunt; Carl Adkin; Michela Guglieri; Emma Ashton; Stephen Abbs; Petros Nihoyannopoulos; Maria Elena Garralda; Mary Rutherford; Caroline McCulley; Linda Popplewell; Ian R Graham; George Dickson; Matthew J A Wood; Dominic J Wells; Steve D Wilton; Ryszard Kole; Volker Straub; Kate Bushby; Caroline Sewry; Jennifer E Morgan; Francesco Muntoni
Journal:  Lancet Neurol       Date:  2009-08-25       Impact factor: 44.182

View more
  1 in total

Review 1.  Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example.

Authors:  Juliana Inês Santos; Mariana Gonçalves; Liliana Matos; Luciana Moreira; Sofia Carvalho; Maria João Prata; Maria Francisca Coutinho; Sandra Alves
Journal:  Life (Basel)       Date:  2022-04-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.